Sessão de Encontro com o Autor – Tema Livre


Código

P113

Área Técnica

Retina

Instituição onde foi realizado o trabalho

  • Principal: Universidade Federal de São Paulo (UNIFESP)

Autores

  • THIAGO GEORGE CABRAL SILVA (Interesse Comercial: NÃO)
  • Luiz H Lima (Interesse Comercial: NÃO)
  • Júlia Polido (Interesse Comercial: NÃO)
  • Jimmy Duong (Interesse Comercial: NÃO)
  • Luiz Guilherme M Mello (Interesse Comercial: NÃO)
  • Erika A Okuda (Interesse Comercial: NÃO)
  • Akiyoshi Oshima (Interesse Comercial: NÃO)
  • Pedro D Serracarbassa (Interesse Comercial: NÃO)
  • Caio V Regatieri (Interesse Comercial: NÃO)
  • Rubens Belfort Jr (Interesse Comercial: NÃO)

Título

AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AND CLINICAL OUTCOMES CORRELATION AFTER SINGLE INTRAVITREAL INJECTION OF BEVACIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Objetivo

To evaluate the concentration of vascular endothelial growth factor (VEGF) in aqueous humor after a single intravitreal injection of bevacizumab (IVB) in eyes with neovascular age-related macular degeneration (AMD).

Método

In this prospective interventional case series study, 24 eyes of 24 patients with types 1 and 2 choroidal neovascularization secondary to neovascular AMD were treated with a single intravitreal injection of bevacizumab. Aqueous humor samples were obtained before the intravitreal injection and at one week, one month, and three months follow-up periods. Best-corrected visual acuity (BCVA) and three spectral-domain optical coherence tomography (SD-OCT) parameters (central retinal thickness, macular volume and macular area) were also analyzed and correlated with VEGF expression at the baseline and each follow-up period.

Resultado

All of the ninety-six aqueous humor study taps were well tolerated by the study patients without adverse events. Increased VEGF levels (mean+/-SD = 179.7 +/- 88.3 pg/mL) were observed in the aqueous humor of all study patients before the intravitreal injection of bevacizumab. At all follow-up periods, compared to baseline, levels of VEGF significantly reduced (P < 0.0001), and BCVA significantly improved (P < 0.005). The lowest VEGF expression was observed at 1 week, and the greatest BCVA improvement occurred 1 month after treatment. At 1 month, central retinal thickness (CRT), macular volume (MV), and macular area (MA) significantly reduced compared to baseline (P < 0.0001, P = 0.0005, P = 0.007, P = 0.009, respectively). At 1 week and 3 months, although without statistical significance (P > 0.005), CRT, MV and MA also reduced in comparison to baseline.

Conclusão

Single intravitreal bevacizumab injection in eyes with neovascular AMD resulted in a substantial decrease of aqueous VEGF levels 1 week after treatment with the greatest improvement of clinical outcomes occurring at 1 month follow-up.

Realização

Realização - CBO

Organização

Arx

Transportadora Aérea Oficial

Latam

Transportadora Oficial

Shuttle

Agência de Transfer Oficial

ClaraTur

Agência Oficial

Naja Turismo

Agência Web

Sistema de Gerenciamento desenvolvido por Inteligência Web

Cota Platina

Apoio

UNIMED

Apoio Institucional

SNNO
Sociedade Cearense de Oftalmologia

61º Congresso Brasileiro de Oftalmologia

6 a 9 de setembro | Fortaleza | Ceará | Brasil